Regulus jumps on promising early data of kidney disease treatment

Regulus Therapeutics

12/09/2022 14:21

** Shares of Regulus Therapeutics Inc  RGLS.O  jump 13.1% to
$1.9 before the bell
    ** Co says its experimental therapy to treat a genetic
kidney disorder has shown to be safe and well-tolerated among
participants in an early-stage study  urn:newsml:reuters.com:*:nPn5CK697a
    ** Autosomal Dominant Polycystic Kidney Disease is a
condition in which fluid cysts develops in kidney, affecting its
functionality  
    ** Up to Friday's close, stock lost ~47% YTD 

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))